These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8958370)

  • 1. Perhexiline--stable plasma concentrations with formulation change.
    Siebert WJ; Gabb GM; Wing LM
    Aust N Z J Med; 1996 Oct; 26(5):707-8. PubMed ID: 8958370
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC; Westley IS; Morris RG
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
    Ling LH; Chik W; Averbuj P; Pati PK; Sverdlov AL; Ngo DT; Morris RG; Sallustio BC; Horowitz JD
    Ther Drug Monit; 2011 Apr; 33(2):251-6. PubMed ID: 21383654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic monitoring of the anti-anginal drug perhexiline maleate.
    Cooper JD; Turnell DC; Pilcher J; Lockhart D
    Ann Clin Biochem; 1985 Nov; 22 ( Pt 6)():614-7. PubMed ID: 4073793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations of long-term treatment with perhexiline maleate using therapeutic monitoring and electromyography.
    Pilcher J; Cooper JD; Turnell DC; Matenga J; Paul R; Lockhart JD
    Ther Drug Monit; 1985; 7(1):54-60. PubMed ID: 3992623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.
    Chong CR; Drury NE; Licari G; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1485-91. PubMed ID: 26376650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
    Sallustio BC; Morris RG
    Ther Drug Monit; 1999 Aug; 21(4):389-94. PubMed ID: 10442691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
    Philpott A; Chandy S; Morris R; Horowitz JD
    Intern Med J; 2004 Jun; 34(6):361-3. PubMed ID: 15228400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
    Stewart S; Voss DW; Northey DL; Horowitz JD
    Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
    Jones TE; Morris RG; Horowitz JD
    Br J Clin Pharmacol; 2004 Mar; 57(3):263-9. PubMed ID: 14998422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of a new anti-angina agent: perhexiline maleate].
    Linquette M; Mesmacque R; Benoit G
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1313-5. PubMed ID: 4802930
    [No Abstract]   [Full Text] [Related]  

  • 13. Tanshinone IIA - loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation.
    Yan HX; Li J; Li ZH; Zhang WL; Liu JP
    Eur J Pharm Sci; 2015 Aug; 76():156-64. PubMed ID: 25976225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of angina pectoris with low-dose perhexiline.
    Horgan JH; O'Callaghan WG; Teo KK
    J Cardiovasc Pharmacol; 1981; 3(3):566-72. PubMed ID: 6168837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
    Tseng CC; Noordali H; Sani M; Madhani M; Grant DM; Frenneaux MP; Zanda M; Greig IR
    J Med Chem; 2017 Apr; 60(7):2780-2789. PubMed ID: 28277663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Method for the analysis of perhexiline and its hydroxy metabolite in plasma using high-performance liquid chromatography with precolumn derivatization.
    Grgurinovich N
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(1):75-80. PubMed ID: 9300911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
    Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
    Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings: A long-term assessment of perhexiline maleate in the management of patients with angina pectoris.
    Gitlin N
    Postgrad Med J; 1973 Apr; 49():Suppl 3:119-20. PubMed ID: 4587028
    [No Abstract]   [Full Text] [Related]  

  • 19. Proceedings: Long-term assessment of perhexiline maleate in angina pectoris.
    Pilcher J; Chandrasekhar KP; Rees JR; Boyce MJ; Peirce TH; Ikram H
    Postgrad Med J; 1973 Apr; 49():Suppl 3:115-8. PubMed ID: 4587027
    [No Abstract]   [Full Text] [Related]  

  • 20. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope.
    Phan TT; Shivu GN; Choudhury A; Abozguia K; Davies C; Naidoo U; Ahmed I; Yousef Z; Horowitz J; Frenneaux M
    Eur J Heart Fail; 2009 Sep; 11(9):881-6. PubMed ID: 19656806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.